RxDoctor Payments Data

Shefali Patel, MD

Internal Medicine · Edison, NJNPI 1982694857

Payments from drug & device makers

$395in general payments, 2019–2025

Across 21 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$143
  • Intra-sana Laboratories$108
  • Novo Nordisk$28
  • Novartis$25
  • Exeltis, USA Inc.$25
  • Meditrina$23
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$395100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$395 in reported general payments places this provider in the 50th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$201,613
Medicare patients
237
Services billed
2,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium596$354,626
JanuviaSitagliptin Phosphate179$145,599
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate26$136,164
JanumetSitagliptin Phos/Metformin Hcl128$103,815
FarxigaDapagliflozin Propanediol116$101,563
Lactulose30$87,820
OzempicSemaglutide51$70,115
TradjentaLinagliptin93$70,001
Metformin Hcl556$43,566
EliquisApixaban35$27,647
JardianceEmpagliflozin24$26,297
RybelsusSemaglutide22$22,487
TrulicityDulaglutide14$17,982
Metformin Er GastricMetformin Hcl17$16,923
Diclofenac Potassium12$16,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$143$105,866128 claims
Novo NordiskOzempic, Rybelsus$28$92,60273 claims
PfizerEliquis$15$27,64735 claims
GSKBreo Ellipta$17$6,59714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →